Prolacta's innovative fortifiers gain prescription status for neonatal care.
- Japan becomes the first country to approve 100% human milk-based fortifiers.
- These fortifiers are designed for premature and vulnerable infants.
- Prolacta's products aim to improve nutritional outcomes in neonatal care.
Japan has officially approved Prolacta Biosciences' 100% human milk-based fortifiers as a prescription drug for vulnerable infants. This groundbreaking decision represents a significant advancement in neonatal care, focusing specifically on premature and low-birth-weight infants who face higher nutritional challenges. The use of human milk in infant nutrition is gaining prominence due to its health benefits for newborns.
The approval highlights the potential of these fortifiers to improve health outcomes for infants in need, ensuring that they receive optimum nutrition early in their lives. Prolacta's products are designed to be used alongside breast milk, providing essential nutrients that can support growth and development in premature babies. This development in Japan aligns with a growing trend toward using human milk-derived products in infant nutrition.
Prior to this approval, there has been a notable demand for effective nutritional solutions for vulnerable infants, as traditional options may not meet their specific needs. By integrating human milk-based fortifiers into neonatal care, Japan is positioning itself as a leader in advancing practices that prioritize the health and well-being of newborns.
